LT3 (liothyronine)
Phase 3Small molecule
LT3 (liothyronine) is one of 19 small molecule programs targeting Hypothyroidism. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
43 competitors in Hypothyroidism
#DrugCompanyPhaseTrials
1Synthroid
IInstitut Jerome Lejeune
Approved
Tricor
JJagotec
Approved
Growth Hormone
PfizerApproved
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Triiodothyronine
HHadassah Medical Organization
Approved
L-Carnitine
IIperboreal Pharma Srl
Approved
Calcitonin
TTarsa Therapeutics, Inc.
Approved
Levothyroxin
BBerlin-Chemie AG Menarini Group
Approved
L-Thyroxine
SShandong Provincial Hospital
Approved
Farxiga
AstraZenecaPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LT3 (liothyronine). EMBL-EBI & Wellcome Sanger Institute.
- [4]